BR112021017637A8 - Vírus oncolítico sintético, composição farmacêutica, e, método para tratar câncer - Google Patents

Vírus oncolítico sintético, composição farmacêutica, e, método para tratar câncer

Info

Publication number
BR112021017637A8
BR112021017637A8 BR112021017637A BR112021017637A BR112021017637A8 BR 112021017637 A8 BR112021017637 A8 BR 112021017637A8 BR 112021017637 A BR112021017637 A BR 112021017637A BR 112021017637 A BR112021017637 A BR 112021017637A BR 112021017637 A8 BR112021017637 A8 BR 112021017637A8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
treat cancer
oncolytic virus
synthetic oncolytic
synthetic
Prior art date
Application number
BR112021017637A
Other languages
English (en)
Other versions
BR112021017637A2 (pt
Inventor
J Irvine Darrell
Dane Wittrup Karl
Weiss Ron
Li Yingzhong
Momin Noor
Dong Yizhou
Original Assignee
Massachusetts Inst Technology
Univ Ohio State
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology, Univ Ohio State, Ohio State Innovation Foundation filed Critical Massachusetts Inst Technology
Publication of BR112021017637A2 publication Critical patent/BR112021017637A2/pt
Publication of BR112021017637A8 publication Critical patent/BR112021017637A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Abstract

VÍRUS ONCOLÍTICO SINTÉTICO, COMPOSIÇÃO FARMACÊUTICA, E, MÉTODO PARA TRATAR CÂNCER. A presente descrição se refere aos vírus oncolíticos sintéticos compreendendo uma nanopartícula lipídica compreendendo um ou mais tipos de lipídeo e um replicon RNA autoamplificante compreendendo uma sequência que codifica uma molécula imunomodulatória.
BR112021017637A 2019-03-08 2020-01-10 Vírus oncolítico sintético, composição farmacêutica, e, método para tratar câncer BR112021017637A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962815611P 2019-03-08 2019-03-08
PCT/US2020/013069 WO2020185293A1 (en) 2019-03-08 2020-01-10 Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy

Publications (2)

Publication Number Publication Date
BR112021017637A2 BR112021017637A2 (pt) 2021-11-09
BR112021017637A8 true BR112021017637A8 (pt) 2022-08-16

Family

ID=69526302

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021017637A BR112021017637A8 (pt) 2019-03-08 2020-01-10 Vírus oncolítico sintético, composição farmacêutica, e, método para tratar câncer

Country Status (13)

Country Link
US (2) US11717548B2 (pt)
EP (1) EP3934673A1 (pt)
JP (1) JP2022524391A (pt)
KR (1) KR20220006041A (pt)
CN (1) CN113966221A (pt)
AU (1) AU2020233788A1 (pt)
BR (1) BR112021017637A8 (pt)
CA (1) CA3132714A1 (pt)
CO (1) CO2021013417A2 (pt)
IL (1) IL285963A (pt)
MX (1) MX2021010808A (pt)
SG (1) SG11202109514VA (pt)
WO (1) WO2020185293A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113509542A (zh) * 2021-04-20 2021-10-19 嘉晨西海(杭州)生物技术有限公司 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法
WO2023212618A1 (en) 2022-04-26 2023-11-02 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
CN115227674B (zh) * 2022-08-05 2023-07-04 武汉滨会生物科技股份有限公司 包封的溶瘤病毒遗传物质及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
SI2590676T1 (sl) 2010-07-06 2016-11-30 Glaxosmithkline Biologicals, S.A. Virionu podobni delci za dajanje za samorepliciranje RNA molekul
WO2016037053A1 (en) 2014-09-05 2016-03-10 Novartis Ag Lipids and lipid compositions for the delivery of active agents
EP3939571A1 (en) * 2015-05-21 2022-01-19 Ohio State Innovation Foundation Benzene-1,3,5-tricarboxamide derivatives and uses thereof

Also Published As

Publication number Publication date
EP3934673A1 (en) 2022-01-12
KR20220006041A (ko) 2022-01-14
US11717548B2 (en) 2023-08-08
CN113966221A (zh) 2022-01-21
JP2022524391A (ja) 2022-05-02
CA3132714A1 (en) 2020-09-17
CO2021013417A2 (es) 2022-01-17
US20200281994A1 (en) 2020-09-10
IL285963A (en) 2021-10-31
MX2021010808A (es) 2021-12-15
WO2020185293A1 (en) 2020-09-17
AU2020233788A1 (en) 2021-10-07
SG11202109514VA (en) 2021-09-29
US20240024394A1 (en) 2024-01-25
BR112021017637A2 (pt) 2021-11-09

Similar Documents

Publication Publication Date Title
BR112021017637A8 (pt) Vírus oncolítico sintético, composição farmacêutica, e, método para tratar câncer
BR112018013930A2 (pt) vírus oncolítico, vírus que expressa três genes heterólogos, composição farmacêutica, vírus para o uso, produto de fabricação, método de tratamento de câncer e uso do vírus
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
CY1123845T1 (el) Τοπικα φαρμακευτικα σκευασματα για την αγωγη φλεγμονωδων καταστασεων
BR112019000015A2 (pt) distribuição por vírus oncolítico pseudotipado de polipeptídeos terapêuticos
CL2019002912A1 (es) Métodos para detectar aav. (divisional solicitud 201900392).
BR112018077266A2 (pt) composições compreendendo cepas bacterianas
BR112019005305A2 (pt) compostos espirocíclicos
BR112018073238A2 (pt) vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer
BR112018009009A2 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
BR112016003127A2 (pt) “composições e métodos para modular rna”
BR112018013995A2 (pt) terapia de combinação de vírus oncolítico e inibidor de ponto de verificação
BR112016023769A2 (pt) célula hospedeira recombinante para a expressão de proteínas de interesse
BR112019004297A2 (pt) método, uso de uma quantidade eficaz de um composto, composto, e, composição farmacêutica.
BR112019001852A2 (pt) composição de cannabis
BR112017009545B8 (pt) Composição antibacteriana farmacêutica ou veterinária e método in vitro para a preparação de uma composição farmacêutica ou veterinária
BR112015025748A2 (pt) construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna
BR112021023024A2 (pt) Anticorpo contra claudina 18a2 e uso do mesmo
BR112019002573A2 (pt) pneu, padrão de banda de rodagem, e, método para aumentar a resistência ao arrancamento e ao craqueamento de uma banda de rodagem de um pneu
BR112018069927A2 (pt) terapia de câncer com um vírus oncolítico combinado com um inibidor de ponto de verificação
BR112017021191A2 (pt) um extrato de indigo naturalis e um processo para preparar o mesmo
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
BR112017004770A2 (pt) partícula tipo flavivírus
BR102017028271A2 (pt) sistema e processo de monitoramento de desempenhos de aplicativos do sistema informático
BR112018000074A2 (pt) micro-organismo para produzir l-lisina e método para produzir l-lisina com o uso do mesmo

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) ; OHIO STATE INNOVATION FOUNDATION (US)